- |||||||||| Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly, Focus V (anlotinib) / Advenchen, Sino Biopharm
P2 data, Journal, PD(L)-1 Biomarker, IO biomarker, Metastases: Sintilimab plus anlotinib as second- or third-line therapy in metastatic non-small cell lung cancer with uncommon epidermal growth factor receptor mutations: A prospective, single-arm, phase II trial. (Pubmed Central) - Oct 22, 2023 P2 The combination of sintilimab and anlotinib demonstrated durable efficacy and was generally well tolerated in patients with NSCLC and uncommon EGFR mutations who had received prior standard-of-care treatments. (ClinicalTrials.gov identifier: NCT04790409).
- |||||||||| Avastin (bevacizumab) / Roche, Focus V (anlotinib) / Advenchen, Sino Biopharm
Review, Journal: Treatment of neurofibromatosis type II with anlotinib: a case report and literature review. (Pubmed Central) - Oct 22, 2023 Here, we present a case of NF2 that developed exacerbations after multiple treatments with gamma knife and surgery, and achieved good results after later treatment with anlotinib. Accordingly, we propose that anlotinib may be a valuable treatment option for NF2.
- |||||||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal: Chemotherapy regimen for recurrent uterine leiomyosarcoma. (Pubmed Central) - Oct 3, 2023 Conclusions Anlotinib plus chemotherapy as first-line treatment has shown promising efficacy and acceptable safety and maybe a favorable option for advanced LMs CRC tumors. It is important to comprehensively consider the patient's condition, and fully consider the efficacy, dosage, and adverse reactions of the chemotherapy regimen to determine the appropriate plan, in order to achieve the best therapeutic benefits for patients.
- |||||||||| AiTan (rivoceranib) / HLB Bio Group
Biomarker, Trial completion date, Trial primary completion date, Metastases: BIOVAS: BIOmarker Driven Trial of VEGFR2 Inhibitor in Advanced Sarcoma (clinicaltrials.gov) - Oct 3, 2023 P2, N=30, Recruiting, It is important to comprehensively consider the patient's condition, and fully consider the efficacy, dosage, and adverse reactions of the chemotherapy regimen to determine the appropriate plan, in order to achieve the best therapeutic benefits for patients. Trial completion date: Aug 2023 --> May 2024 | Trial primary completion date: Feb 2023 --> Feb 2024
- |||||||||| AL8326 / Advenchen
Trial completion date, Trial primary completion date: Phase 2 Safety and Efficacy Evaluation of AL8326 in ?2nd Line SCLC (clinicaltrials.gov) - Oct 3, 2023 P2, N=36, Recruiting, Trial completion date: Aug 2023 --> May 2024 | Trial primary completion date: Feb 2023 --> Feb 2024 Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
- |||||||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
P2 data, Journal, Metastases: Anlotinib as a maintenance treatment for advanced soft tissue (Pubmed Central) - Sep 28, 2023 P2 Postchemotherapy maintenance treatment with anlotinib exhibits promising efficacy and tolerable toxicity in patients with advanced STS. Chia Tai Tianqing Pharmaceutical Group Co., Ltd., the National Key Research and Development Program of China, and the National Natural Science Foundation of China.
- |||||||||| Tyvyt (sintilimab) / Innovent Biologics, Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial completion date, Trial primary completion date, Metastases: Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC) (clinicaltrials.gov) - Sep 26, 2023 P2, N=30, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., the National Key Research and Development Program of China, and the National Natural Science Foundation of China. Trial completion date: Dec 2021 --> Dec 2023 | Trial primary completion date: Aug 2021 --> Dec 2023
- |||||||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial primary completion date, Metastases: Anlotinib Combination With Vinorelbine in the HER2- Advanced Breast Cancer (clinicaltrials.gov) - Sep 25, 2023 P2, N=134, Recruiting, This approach was successful in these patients, but a larger sample size is required to verify our findings. Trial primary completion date: May 2023 --> Sep 2024
- |||||||||| Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly, Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial completion, Tumor mutational burden, IO biomarker, Metastases: Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon Mutations (clinicaltrials.gov) - Sep 14, 2023 P2, N=21, Completed, The efficacy of anlotinib may be impaired by previous antiangiogenic therapy, which can be investigated in further studies. Active, not recruiting --> Completed
- |||||||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial primary completion date: Anlotinib Capsules in the Treatment for IPF/PF-ILDs (clinicaltrials.gov) - Sep 13, 2023 P2/3, N=30, Recruiting, Active, not recruiting --> Completed Trial primary completion date: Jul 2023 --> Jul 2024
- |||||||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Clinical, Journal, HEOR, Cost-effectiveness, Cost effectiveness, Metastases: Cost-effectiveness analysis of anlotinib as a third-line or further treatment for advanced non-small cell lung cancer in China. (Pubmed Central) - Sep 11, 2023 The cost-effectiveness acceptability curves showed that the base-case analysis results were relatively stable. Considering the clinical efficacy, safety, and cost-effectiveness of anlotinib, it may be a valuable third-line or further treatment for advanced NSCLC in China.
- |||||||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal: Anlotinib Attenuates Liver Fibrosis by Regulating the Transforming Growth Factor ?1/Smad3 Signaling Pathway. (Pubmed Central) - Sep 8, 2023 In animal experiments, anlotinib showed protective effects on the CCl4-induced liver damage, including ameliorating liver inflammation, reversing liver fibrosis and reducing liver enzymes. This is a very good signal, anlotinib may be useful for halting or reversing the progression of liver fibrosis and could be employed in the development of novel therapeutic drugs for the management of chronic liver diseases.
|